Company / Return on Equity (ROE)
Ensysce Biosciences, Inc. Return on Equity (ROE) History
FY2024-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
-248.5%
FY2025
5-year range
-286.5% / -248.5%
FY2024-FY2025
Trend
+13.3%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Ensysce Biosciences, Inc. reports negative total equity of -248.5% in FY2025. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-248.5% in FY2025.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- -
- 5-Year Change
- -
- 10-Year Change
- -
Key checks
Key Insights
- In FY2025, return on equity (roe) increased 13.3% year-over-year.
Company context
Key Data Points
- Altman Z-Score -1.53 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -248.5% | +13.3% |
| FY2024 | -286.5% | - |
| FY2023 | - | - |
| FY2022 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026